MEASURE SPECIFICATIONS

Cancer Programs Practice Profile Reports (*CP³R*)
Rapid Quality Reporting System (RQRS)

Introduction

The Commission on Cancer's (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve the transparency with which the measures in the CP³R and RQRS reporting systems are calculated. To this end, a definitive list of cancer registry data items used in the evaluation of each measure, the selection criteria used to identify cases in the denominator of each measure, and the logic used to distinguish between concordant and non-concordant cases are presented in easy-to-read tables. Finally, a flow-diagram illustrating the steps as each case is evaluated for consideration and assessment in a measure is provided.

Note: the specifications documented here DO NOT constitute a change in the methodology used or specifications applied in the assessment of these measures presented in either the CP³R or RQRS.

Measure Definitions

This document provides specifications for the following three measures:

- (NQF #0559) Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer.
- (NQF #0220) Tamoxifen *or* third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or Stage II or III hormone receptor positive breast cancer.
- (NQF #0223) Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer.

Similarly formatted specifications for the other three measures reported in the CP³R and RQRS reporting systems will be forthcoming.

For each measure, three tables and a flow-diagram are provided:

- The *Measure Item List* table listing each cancer registy data item used in the assessment of the indicated measure. This includes the FORDS data item name, the North American Associtaion of Central Cancer Registry (NAACCR) item number, and a brief description of each item.
- The *Case Eligibility Criteria* table itemizes the steps taken to determine whether cases belong in the measure denominator. Each condition is described and is accompanied by the data item and code values used in the assesment.
- The *Numerator Criteria* table illustrates how cases are assessed to determine whether they qualify for the numerator of the measure, i.e. are concordant.
- A flow-diagram is provided to illustrate the steps through which cases pass as they are evaluted for the indicated measure. The number appearing in each flow-diagram element corresponds to the assessment criteria appearing in the *Case Eligibility Criteria* and *Numerator Criteria* tables.

Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under the age of 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer.

Measure Item List		
FORDS Data Item	**NAACCR #**	**Description**
Primary Site	400	Organ of origin of the cancer
Sex	220	Sex of patient
Age at Diagnosis	230	Age of patient at diagnosis
Sequence Number	560	Sequence of malignant and nonmalignant neoplasms over the lifetime of the patient
Histology	522	Microscopic or cellular anatomy of the cancer
Behavior Code	532	Neoplastic behavior of the cancer
Class of Case	610	Indicates the reporting facility's role in managing the cancer
Clinical M	960	AJCC Clinical M
Pathologic M	900	AJCC Pathologic M
Clinical Stage Group	970	AJCC Clinical Stage Group
Pathologic Stage Group	910	AJCC Pathologic Stage Group
Surgical Procedure of the Primary Site	1290	Surgical procedure performed on the primary site of the cancer
Date of Initial Diagnosis	390	Date of initial diagnosis by a physician of the cancer
Date of Last Contact or Death	1750	Date of last contact with the patient, or date of patient death
Vital Status	1770	Vital status of the patient, as of the date of last contact or death
CS Tumor Size	2800	Largest dimension of the primary tumor, in millimeters
Pathologic N	890	AJCC Pathologic N
CS Site Specific Factor 1	2880	ERA
CS Site Specific Factor 2	2890	PRA
Chemotherapy	1390	Type of chemotherapy administered as first course treatment for the cancer, at the reporting facility and all other facilities

Date Chemotherapy Started	1220	Date of initiation of chemotherapy

Case Eligibility Criteria			
Diagram Reference	**Assessment**	**Item**	**Codes**
1	Diagnosis of breast cancer	Primary Site	C50.0, C50.1, C50.2, C50.3, C50.4, C50.5, C50.6, C50.8, C50.9
2	Female patients only	Sex	2
3	Adult patient under the age of 70 at diagnosis	Age at Diagnosis	018 - 069
4	First or only diagnosis of malignant or non-malignant neoplasm	Sequence Number	00 or 01
5	Epithelial tumors which can be staged, according to the AJCC 7th Ed.	Histology	8000-8576; 8940-8950; 8980-8981; 9020
6	Invasive tumors	Behavior Code	3
7	Clinical or pathologic evidence of in situ disease (exclude)	Clinical Stage Group	<> 0, IS
		Pathologic Stage Group	<> 0, IS
8	Clinical or pathologic evidence of metastatic disease (exclude)	Clinical Stage Group	<> 4
		Pathologic Stage Group	<> 4
		Clinical M	<> 1
		Pathologic M	<> 1
9	All or part of the first course of treatment was performed at the reporting facility	Class of Case	10-22
10	Surgically treated	Surgical Procedure of the Primary Site	20 - 90
11	Patient reported living within the treatment timeframe period of 120 days from date of diagnosis	Date of Initial Diagnosis	# Elapsed days > 120 ***OR*** # Elapsed days <=120 AND Vital Status = 1
		Date of Last Contact or Death	
		Vital Status	

12	AJCC T1cN0M0 tumor OR AJCC Stage II or III tumor	CS Tumor Size	11 - 989, 992 - 995
		Pathologic N	0, I-, 0I-, I+, 0I+, M-, 0M-, M+, 0M+
		OR	
		Pathologic N	1, 1M, 1MI, 1A, 1B, 1C, 2, 2A, 2B, 3, 3A, 3B, 3C
13	Hormone Receptor Negative	CS Site Specific Factor 1	20
		CS Site Specific Factor 2	20, 30
		OR	
		CS Site Specific Factor 1	30
		CS Site Specific Factor 2	20

Numerator Criteria			
Diagram Reference	**Assessment**	**Item**	**Codes**
14	Chemotherapy Administered within 120 days following Diagnosis	Chemotherapy	03 AND # Elapsed days <= 120
		Date of Initial Diagnosis	
		Date Chemotherapy Started	
	OR		
	Chemotherapy Considered/Recommended, but not Administered	Chemotherapy	82, 85, 86, 87

Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer.



Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or Stage III hormone receptor positive breast cancer.

Measure Item List		
FORDS Data Item	**NAACCR #**	**Description**
Primary Site	400	Organ of origin of the cancer
Sex	220	Sex of patient
Age at diagnosis	230	Age of patient at diagnosis
Sequence Number	560	Sequence of malignant and nonmalignant neoplasms over the lifetime of the patient
Histology	522	Microscopic or cellular anatomy of the cancer
Behavior Code	532	Neoplastic behavior of the cancer
Class of Case	610	Indicates the reporting facility's role in managing the cancer
Clinical M	960	AJCC Clinical M
Pathologic M	900	AJCC Pathologic M
Clinical Stage Group	970	AJCC Clinical Stage Group
Pathologic Stage Group	910	AJCC Pathologic Stage Group
Surgical Procedure of the Primary Site	1290	Surgical procedure performed on the primary site of the cancer
Date of Initial Diagnosis	390	Date of initial diagnosis by a physician of the cancer
Date of Last Contact or Death	1750	Date of last contact with the patient, or date of patient death
Vital Status	1770	Vital status of the patient, as of the date of last contact or death
CS Tumor Size	2800	Largest dimension of the primary tumor, in millimeters
Pathologic N	890	AJCC Pathologic N
CS Site Specific Factor 1	2880	ERA
CS Site Specific Factor 2	2890	PRA
Hormone Therapy	1400	Type of hormone therapy administered as first course treatment for the cancer, at

		the reporting facility and all other facilities
Date Hormone Therapy Started	1230	Date of initiation of hormone therapy

Case Eligibility Criteria			
Diagram Reference	**Assessment**	**Item**	**Codes**
1	Diagnosis of breast cancer	Primary Site	C50.0, C50.1, C50.2, C50.3, C50.4, C50.5, C50.6, C50.8, C50.9
2	Female patients only	Sex	2
3	Adult patient at diagnosis	Age at Diagnosis	>= 018
4	First or only diagnosis of malignant or non-malignant neoplasm	Sequence Number	00 or 01
5	Epithelial tumors which can be staged, according to the AJCC 7th Ed.	Histology	8000-8576; 8940-8950; 8980-8981; 9020
6	Invasive tumors	Behavior Code	3
7	Clinical or pathologic evidence of in situ disease (exclude)	Clinical Stage Group	<> 0, IS
		Pathologic Stage Group	<> 0, IS
8	Clinical or pathologic evidence of metastatic disease (exclude)	Clinical Stage Group	<> 4
		Pathologic Stage Group	<> 4
		Clinical M	<> 1
		Pathologic M	<> 1
9	All or part of the first course of treatment was performed at the reporting facility	Class of Case	10-22
10	Surgically treated	Surgical Procedure of the Primary Site	20 - 90
11	Patient reported living within the treatment timeframe period of 365 days from date of diagnosis	Date of Initial Diagnosis	# Elapsed days > 365 ***OR*** # Elapsed days <=365 AND Vital Status = 1
		Date of Last Contact or Death	
		Vital Status	

12	AJCC T1cN0M0 tumor OR AJCC Stage II or III tumor	CS Tumor Size	11 - 989, 992 - 995
		Pathologic N	0, I-, 0I-, I+, 0I+, M-, 0M-, M+, 0M+
		OR	
		Pathologic N	1, 1M, 1MI, 1A, 1B, 1C, 2, 2A, 2B, 3, 3A, 3B, 3C
13	Hormone Receptor Positive	CS Site Specific Factor 1	10, 30
		OR	
		CS Site Specific Factor 2	10, 30

Numerator Criteria			
Diagram Reference	**Assessment**	**Item**	**Codes**
14	Hormone Therapy Administered within 365 days following Diagnosis	Hormone Therapy	01 AND # Elapsed days <= 365
		Date of Initial Diagnosis	
		Date Hormone Therapy Started	
	OR		
	Hormone Therapy Considered/Recommended, but not Administered	Hormone Therapy	82, 85, 86, 87

Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or Stage III hormone receptor positive breast cancer



Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer

Measure Item List		
FORDS Data Item	**NAACCR #**	**Description**
Primary Site	400	Organ of origin of the cancer
Age at Diagnosis	230	Age of patient at diagnosis
Sequence Number	560	Sequence of malignant and nonmalignant neoplasms over the lifetime of the patient
Histology	522	Microscopic or cellular anatomy of the cancer
Behavior Code	532	Neoplastic behavior of the cancer
Class of Case	610	Indicates the reporting facility's role in managing the cancer
Clinical M	960	AJCC Clinical M
Pathologic M	900	AJCC Pathologic M
Clinical Stage Group	970	AJCC Clinical Stage Group
Pathologic Stage Group	910	AJCC Pathologic Stage Group
Surgical Procedure of the Primary Site	1290	Surgical procedure performed on the primary site of the cancer
Date of Initial Diagnosis	390	Date of initial diagnosis by a physician of the cancer
Date of Last Contact or Death	1750	Date of last contact with the patient, or date of patient death
Vital Status	1770	Vital status of the patient, as of the date of last contact or death
Regional Nodes Positive	820	Number of regional lymph nodes examined pathologically and found to contain metastases
Pathologic N	890	AJCC Pathologic N
Chemotherapy	1390	Type of chemotherapy administered as first course treatment for the cancer, at the reporting facility and all other facilities
Date Chemotherapy Started	1220	Date of initiation of chemotherapy

Case Eligibility Criteria			
Diagram Reference	**Assessment**	**Item**	**Codes**
1	Diagnosis of colon cancer	Primary Site	C18.0, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9
2	Adult patient under the age of 80 at diagnosis	Age at Diagnosis	018 - 079
3	First or only diagnosis of malignant or non-malignant neoplasm	Sequence Number	00 or 01
4	Epithelial tumors which can be staged, according to the AJCC 7th Ed.	Histology	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981
5	Invasive tumors	Behavior Code	3
6	Clinical or pathologic evidence of in situ disease (exclude)	Clinical Stage Group	<> 0, IS
		Pathologic Stage Group	<> 0, IS
7	Clinical or pathologic evidence of metastatic disease (exclude)	Clinical Stage Group	<> 4
		Pathologic Stage Group	<> 4
		Clinical M	<> 1
		Pathologic M	<> 1
8	All or part of the first course of treatment was performed at the reporting facility	Class of Case	10-22
9	Surgically treated	Surgical Procedure of the Primary Site	30 – 90
10	Patient reported living within the treatment timeframe period of 120 days from date of diagnosis	Date of Initial Diagnosis	# Elapsed days > 120 ***OR*** # Elapsed days <=120 AND Vital Status = 1
		Date of Last Contact or Death	
		Vital Status	

11	Lymph node positive Disease	Regional nodes positive	1-90, 95, 97

Numerator Criteria			
Diagram Reference	**Assessment**	**Item**	**Codes**
12	Chemotherapy Administered within 120 days following Diagnosis	Chemotherapy	01, 02, 03 AND # Elapsed days <= 120
		Date of Initial Diagnosis	
		Date Chemotherapy Started	
	OR		
	Chemotherapy Considered/Recommended, but not Administered	Chemotherapy	82, 85, 86, 87

Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer